Article(id=1329869645458289018, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869572141855203, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.02.001, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1673798400000, receivedDateStr=2023-01-16, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794995231259, onlineDateStr=2026-11-18, pubDate=1675958400000, pubDateStr=2023-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794995231259, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794995231259, creator=13701087609, updateTime=1794995231259, updator=13701087609, issue=Issue{id=1329869572141855203, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='2', pageStart='105', pageEnd='196', issueExtLink='null', onlineDate='null', pubDate='1675958400000', pubDateStr='2023-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794995213780, creator='13701087609', updateTime=1794995798529, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329872025146995085, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869572141855203, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329872025146995086, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869572141855203, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=105, endPage=112, ext={EN=ArticleExt(id=1329869645647032699, articleId=1329869645458289018, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Clinical research progress in immunotherapy of tumor infiltrating lymphocytes, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Tumor-infiltrating lymphocytes (TIL) has a high degree of heterogeneity. Adoptive cellular immunotherapy is one of the important treatments of immunotherapy. It is effective in many advanced solid tumors treatment with few adverse reactions through TIL reinfusing after expansion in vitro. TIL also has the the role of the effectiveness of anti-tumor therapy. This article reviewed the clinical research progress of TIL therapy in different types of cancer, the research progress of TIL as a predictor of tumor prognosis, and the problems faced by TIL therapy, in order to provide the evidence for follow-up research and the clinical use of TIL therapy.

, authors=Na NI1, Xuejun PAN2, Xia ZHAO2, Zhilong LAN2, Yu HUANG2, Junlong WANG1, *, Bin ZHOU2, *, authorsList=Na NI, Xuejun PAN, Xia ZHAO, Zhilong LAN, Yu HUANG, Junlong WANG, Bin ZHOU, authorCompany=null, correspAuthors=Junlong WANG, Bin ZHOU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329869645919662460, articleId=1329869645458289018, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=肿瘤浸润淋巴细胞免疫治疗的临床研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

肿瘤浸润淋巴细胞(tumor-infiltrating lymphocyte,TIL)具有高度异质性,TIL的过继性细胞免疫治疗作为免疫治疗的重要手段之一,通过对TIL体外扩增后回输,在多种晚期实体肿瘤中具有治疗作用,且不良反应较少。TIL同时还具有评价抗肿瘤治疗预后的作用。现通过对TIL疗法在不同癌种的临床研究进展、TIL作为肿瘤预后的预测指标的研究进展以及TIL疗法面临的问题进行综述,旨在为后续研究以及TIL疗法在临床上的使用提供依据。

, authors=倪娜1, 潘雪君2, 赵霞2, 兰志龙2, 黄宇2, 王俊龙1, *, 周斌2, *, authorsList=倪娜, 潘雪君, 赵霞, 兰志龙, 黄宇, 王俊龙, 周斌, authorCompany=null, correspAuthors=王俊龙, 周斌, authorNote=

倪娜,副研究员,研究方向:创新药物的临床研究。

, correspAuthorsNote=
周斌,研究员,研究方向:社会管理药学研究;
王俊龙,副研究员,研究方向:创新药物的临床研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=/Sr1G//svzpKXYz4tSdPOg==, magXml=asaiUjir99kq138/jPZsUA==, pdfUrl=null, pdf=n+oLZH5yBBo3dkFiRVRRcg==, pdfFileSize=1574886, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=4BYtlZpLRUN1bBWS4HFmpA==, mapNumber=null, fund=null)}, authors=[Author(id=1329869646292955524, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869646376841607, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869646292955524, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869646645277064, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869646292955524, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio={"content":"

倪娜,副研究员,研究方向:创新药物的临床研究。

"}, bioImg=null, bioContent=

倪娜,副研究员,研究方向:创新药物的临床研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646137766269, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=1., ext=[AuthorCompanyExt(id=1329869646146154878, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646137766269, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869646154543487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646137766269, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1329869646733357450, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869646838215052, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869646733357450, language=EN, stringName=Xuejun PAN, firstName=Xuejun, middleName=null, lastName=PAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869646905323917, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869646733357450, language=CN, stringName=潘雪君, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.中国医药工业信息中心,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646209069440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=2., ext=[AuthorCompanyExt(id=1329869646217458049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1329869646230040962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业信息中心,上海 200040)])]), Author(id=1329869646980821391, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869647056318865, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869646980821391, language=EN, stringName=Xia ZHAO, firstName=Xia, middleName=null, lastName=ZHAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869647140204946, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869646980821391, language=CN, stringName=赵霞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.中国医药工业信息中心,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646209069440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=2., ext=[AuthorCompanyExt(id=1329869646217458049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1329869646230040962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业信息中心,上海 200040)])]), Author(id=1329869647211508116, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869647320560022, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647211508116, language=EN, stringName=Zhilong LAN, firstName=Zhilong, middleName=null, lastName=LAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869647400251799, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647211508116, language=CN, stringName=兰志龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.中国医药工业信息中心,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646209069440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=2., ext=[AuthorCompanyExt(id=1329869646217458049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1329869646230040962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业信息中心,上海 200040)])]), Author(id=1329869647463166361, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869647559635355, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647463166361, language=EN, stringName=Yu HUANG, firstName=Yu, middleName=null, lastName=HUANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869647618355612, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647463166361, language=CN, stringName=黄宇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.中国医药工业信息中心,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646209069440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=2., ext=[AuthorCompanyExt(id=1329869646217458049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1329869646230040962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业信息中心,上海 200040)])]), Author(id=1329869647702241694, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869647811293600, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647702241694, language=EN, stringName=Junlong WANG, firstName=Junlong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869647878402465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647702241694, language=CN, stringName=王俊龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646137766269, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=1., ext=[AuthorCompanyExt(id=1329869646146154878, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646137766269, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869646154543487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646137766269, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1329869647949705635, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=6, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869648134255013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647949705635, language=EN, stringName=Bin ZHOU, firstName=Bin, middleName=null, lastName=ZHOU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869648243306918, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647949705635, language=CN, stringName=周斌, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.中国医药工业信息中心,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646209069440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=2., ext=[AuthorCompanyExt(id=1329869646217458049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1329869646230040962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业信息中心,上海 200040)])])], keywords=[Keyword(id=1329869648360747431, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, language=EN, orderNo=1, keyword=anti-cancer immunotherapy), Keyword(id=1329869648440439208, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, language=EN, orderNo=2, keyword=tumor-infiltrating lymphocytes), Keyword(id=1329869648507548073, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, language=EN, orderNo=3, keyword=adoptive cellular immune therapy), Keyword(id=1329869648578851242, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, language=CN, orderNo=1, keyword=抗肿瘤免疫治疗), Keyword(id=1329869648654348715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, language=CN, orderNo=2, keyword=肿瘤浸润淋巴细胞), Keyword(id=1329869648746623404, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, language=CN, orderNo=3, keyword=过继性细胞免疫治疗)], refs=[Reference(id=1329869648947949997, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=杨培培, 昌丽莎, 朱静, 等. 肿瘤浸润淋巴细胞与IncRNA在肿瘤发展中作用的研究进展[J]. 现代肿瘤医学, 2022, 30(6): 1097-1102., articleTitle=null, refAbstract=null), Reference(id=1329869649082167726, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Rosenberg S, Spiess P, Lafreniere R, et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes[J]. Science, 1986, 233(4770): 1318-1321., articleTitle=null, refAbstract=null), Reference(id=1329869649178636719, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Amrendra K, Reese W, Anna EV. Cell therapy with TILs: training and taming T cells to fight cancer[J]. Front Immunol, 2021, 12: 690499., articleTitle=null, refAbstract=null), Reference(id=1329869649279300016, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Amir AJ, Zsiros E, Amaria RN, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma[J]. J Clin Oncol, 2019, 37(15_suppl): 2538., articleTitle=null, refAbstract=null), Reference(id=1329869649342214577, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma[J]. J Clin Oncol, 2021, 39(24): 2656-2666., articleTitle=null, refAbstract=null), Reference(id=1329869649442877874, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study[J]. J Immunother Cancer, 2022, 10(12): e005755., articleTitle=null, refAbstract=null), Reference(id=1329869649518375347, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Iovance Biotherapeutics, Inc. Iovance biotherapeutics provides update on biologics license application submission for lifileucel in advanced melanoma[EB/OL]. [2022-12-15]. https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-provides-update-biologics-license., articleTitle=null, refAbstract=null), Reference(id=1329869649577095604, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Pillai M, Jiang Y, Lorigan PC, et al. Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma[J]. Am J Cancer Res, 2022, 12(8): 3967-3984., articleTitle=null, refAbstract=null), Reference(id=1329869649631621558, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Dafni U, Michielin O, Martin LS, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis[J]. Ann Oncol, 2019, 30(12): 1902-1913., articleTitle=null, refAbstract=null), Reference(id=1329869649702924727, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Mehta GU, Malekzadeh P, Shelton T, et al. Outcomes of adoptive cell transfer with tumor-infiltrating lymphocytes for metastatic melanoma patients with and without brain metastases[J]. J Immunother, 2018, 41(5): 241-247., articleTitle=null, refAbstract=null), Reference(id=1329869649774227896, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040., articleTitle=null, refAbstract=null), Reference(id=1329869649837142457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=赵毅, 邓鑫. 乳腺癌分子分型与治疗策略[J]. 中国实用外科杂志, 2015, 35(7): 704-708., articleTitle=null, refAbstract=null), Reference(id=1329869649900057018, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Lee HJ, Kim YA, Sim CK, et al. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer[J]. Oncotarget, 2017, 8(69): 113345-113359., articleTitle=null, refAbstract=null), Reference(id=1329869649962971579, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Zacharakis N, Huq LM, Seitter SJ, et al. Breast cancers are immunogenic: immunologic analyses and a phase Ⅱ pilot clinical trial using mutation-reactive autologous lymphocytes[J]. J Clin Oncol, 2022, 40(16): 1741-1754., articleTitle=null, refAbstract=null), Reference(id=1329869650021691836, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Mayor P, Starbuck K, Zsiros E, et al. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies[J]. Gynecol Oncol, 2018, 150(2): 361-369., articleTitle=null, refAbstract=null), Reference(id=1329869650072023485, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Stevanovi S, Helman SR, Wunderlich JR, et al. A phase Ⅱstudy of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers[J]. Clin Cancer Res, 2019, 25(5): 1486-1493., articleTitle=null, refAbstract=null), Reference(id=1329869650126549438, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Sakellariou-Thompson D, Forget MA, Hinchcliff E, et al. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy[J]. Cancer Immunol Immunother, 2019, 68(11): 1747-1757., articleTitle=null, refAbstract=null), Reference(id=1329869650189463999, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Jimeno A, Papa S, Haigentz M, et al. Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC[J]. J Immunoth Cancer, 2020, 8(Suppl 3): A378., articleTitle=null, refAbstract=null), Reference(id=1329869650252378560, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=李疆, 张晓实, 莫浩元, 等. 鼻咽癌患者Epstein-Barr (EB)病毒特异性细胞毒性T淋巴细胞转移继发免疫治疗的临床前期研究[C].//第九届全国肿瘤生物治疗学术会议论文集, 2006: 178-180., articleTitle=null, refAbstract=null), Reference(id=1329869650306904513, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Creelan BC, Wang C, Teer JK, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial[J]. Nat Med, 2021, 27(8): 1410-1418., articleTitle=null, refAbstract=null), Reference(id=1329869650382401987, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Massarelli E, Schoenfeld A, Chesney J, et al. A phase 2 multicenter study of iovance autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic NSCLC[J]. J Thorac Oncol, 2021, 16(10): S1012., articleTitle=null, refAbstract=null), Reference(id=1329869650453705156, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Poch M, Hall M, Joerger A, et al. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer[J]. Oncoimmunology, 2018, 7(9): e1476816., articleTitle=null, refAbstract=null), Reference(id=1329869650516619717, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=李江, 陈耀兵, 陈丽君, 等. 自体肿瘤浸润淋巴细胞联合抗程序性死亡受体-1单抗治疗晚期肝癌的临床研究[J]. 临床外科杂志, 2021, 29(8): 743-747., articleTitle=null, refAbstract=null), Reference(id=1329869650583728582, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Veliça P, Zech M, Stauss H, et al. Tuning of mTOR in therapeutic T cells as a strategy to manufacture effector and memory T cells[J]. Blood, 2013, 122(21): 4488., articleTitle=null, refAbstract=null), Reference(id=1329869650642448839, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Khan AB, Carpenter B, Pedro SES, et al. Targeting therapeutic T cells to the bone-marrow niche[J]. Lancet, 2017, 389(1): S55., articleTitle=null, refAbstract=null), Reference(id=1329869650705363400, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Alsaieedi A, Holler A, Velica P, et al. Safety and efficacy of Tet-regulated IL-12 expression in cancer specific T cells[J]. Oncolmmunology, 2019, 8(3): 1542917, articleTitle=null, refAbstract=null), Reference(id=1329869650780860873, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Eggermont A, Robert C, Soria JC, et al. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors[J]. Oncoimmunology, 2014, 3(1): e27560., articleTitle=null, refAbstract=null), Reference(id=1329869650847969738, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Toss MS, Miligy I, Al-Kawaza A, et al. Prognostic significance of tumor – infiltrating lymphocytes in ductal carcinoma in situ of the breast[J]. Mod Pathol, 2018, 31(8): 1226-1236., articleTitle=null, refAbstract=null), Reference(id=1329869650919272907, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Oberg HH, Janitschke L, Sulaj V, et al. Bispecific antibodies enhance tumor – infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors[J]. J Leukoc Biol, 2020, 107(6): 1081-1095., articleTitle=null, refAbstract=null), Reference(id=1329869650990576076, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=杨怀玉, 宣立学. 不同肿瘤浸润淋巴细胞亚型在三阴性乳腺癌中的研究进展[J]. 中华内分泌外科杂志, 2022, 16(2): 237-240., articleTitle=null, refAbstract=null), Reference(id=1329869651053490637, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumor-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3 771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018, 19(1): 40-50., articleTitle=null, refAbstract=null), Reference(id=1329869651116405198, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Würfel F, Erber R, Huebner H, et al. TIL gen: a program to investigate immune targets in breast cancer patients – first results on the influence of tumor-infiltrating lymphocytes[J]. Breast Care (Basel), 2018, 13(1): 8-14., articleTitle=null, refAbstract=null), Reference(id=1329869651166736847, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Hwang WT, Adams SF, Tahirovic E, et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis[J]. Gynecol Oncol, 2012, 124(2): 192-198., articleTitle=null, refAbstract=null), Reference(id=1329869651225457104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=De Jong RA, Leffers N, Boezen HM, et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type Ⅰ and Ⅱ endometrial cancer[J]. Gynecol Oncol, 2009, 114: 105-110., articleTitle=null, refAbstract=null), Reference(id=1329869651288371665, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Hu B, Sun M, Wang Z, et al. Prognostic value of programmed cell death-ligand 1 expression in tumor-infiltrating lymphocytes and viral load in peripheral blood mononuclear cells for Epstein-Barr virus positive nasopharyngeal carcinoma[J]. Clin Chem, 2020, 66(9): 1219-1227., articleTitle=null, refAbstract=null), Reference(id=1329869651368063442, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Hulen T, Chamberlain CA, Svane IM, et al. ACT up TIL now: the evolution of tumor-infiltrating lymphocytes in adoptive cell therapy for the treatment of solid tumors[J]. Immuno, 2021, 1: 194-211., articleTitle=null, refAbstract=null), Reference(id=1329869651451949523, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Vignali D, Kallikourdis M. Improving homing in T cell therapy[J]. Cytokine Growth Factor Rev, 2017, 36: 107-116., articleTitle=null, refAbstract=null), Reference(id=1329869651514864084, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Qu R, Kluger Y, Yang J, et al. Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure[J]. Mol Cancer, 2022, 21(1): 219., articleTitle=null, refAbstract=null), Reference(id=1329869651577778645, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=祝文君, 胡湛斐, 袁周. 肿瘤浸润淋巴细胞在胰腺癌中研究进展[J]. 世界华人消化杂志, 2021, 29(21): 1207-1214., articleTitle=null, refAbstract=null), Reference(id=1329869651640693206, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=邵瑶健, 孟立娜. 肿瘤浸润淋巴细胞在胃癌免疫治疗中的意义[J]. 浙江医学, 2019, 41(22): 2444-2447., articleTitle=null, refAbstract=null), Reference(id=1329869651711996375, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=何天基, 葛波. 肿瘤浸润淋巴细胞在泌尿系肿瘤中的研究进展[J]. 中国免疫学杂志, 2020, 36(14): 1779-1783., articleTitle=null, refAbstract=null), Reference(id=1329869651808465368, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=杨涵, 陈超, 王冲. 肿瘤浸润性淋巴细胞免疫治疗的研究进展[J]. 上海医药, 2022, 43(11): 17-21., articleTitle=null, refAbstract=null), Reference(id=1329869651875574233, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Zheng L, Qin S, Si W, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells[J]. Science, 2021, 374(6574): abe6474., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329869646137766269, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=1., ext=[AuthorCompanyExt(id=1329869646146154878, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646137766269, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869646154543487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646137766269, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)]), AuthorCompany(id=1329869646209069440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=2., ext=[AuthorCompanyExt(id=1329869646217458049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1329869646230040962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业信息中心,上海 200040)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.02.001, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.02.001, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.02.001, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.02.001, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1675958400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
肿瘤浸润淋巴细胞免疫治疗的临床研究进展
倪娜 1 , 潘雪君 2 , 赵霞 2 , 兰志龙 2 , 黄宇 2 , 王俊龙 1, * , 周斌 2, *
世界临床药物 | 医药专论 2023,44(2): 105-112
收起
收藏切换
世界临床药物 |医药专论 2023 , 44 (2) : 105 -112
肿瘤浸润淋巴细胞免疫治疗的临床研究进展
全屏
[Author(id=1329869646292955524, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869646376841607, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869646292955524, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869646645277064, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869646292955524, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio={"content":"

倪娜,副研究员,研究方向:创新药物的临床研究。

"}, bioImg=null, bioContent=

倪娜,副研究员,研究方向:创新药物的临床研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646137766269, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=1., ext=[AuthorCompanyExt(id=1329869646146154878, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646137766269, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869646154543487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646137766269, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1329869646733357450, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869646838215052, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869646733357450, language=EN, stringName=Xuejun PAN, firstName=Xuejun, middleName=null, lastName=PAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869646905323917, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869646733357450, language=CN, stringName=潘雪君, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.中国医药工业信息中心,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646209069440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=2., ext=[AuthorCompanyExt(id=1329869646217458049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1329869646230040962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业信息中心,上海 200040)])]), Author(id=1329869646980821391, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869647056318865, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869646980821391, language=EN, stringName=Xia ZHAO, firstName=Xia, middleName=null, lastName=ZHAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869647140204946, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869646980821391, language=CN, stringName=赵霞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.中国医药工业信息中心,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646209069440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=2., ext=[AuthorCompanyExt(id=1329869646217458049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1329869646230040962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业信息中心,上海 200040)])]), Author(id=1329869647211508116, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869647320560022, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647211508116, language=EN, stringName=Zhilong LAN, firstName=Zhilong, middleName=null, lastName=LAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869647400251799, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647211508116, language=CN, stringName=兰志龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.中国医药工业信息中心,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646209069440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=2., ext=[AuthorCompanyExt(id=1329869646217458049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1329869646230040962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业信息中心,上海 200040)])]), Author(id=1329869647463166361, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869647559635355, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647463166361, language=EN, stringName=Yu HUANG, firstName=Yu, middleName=null, lastName=HUANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869647618355612, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647463166361, language=CN, stringName=黄宇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.中国医药工业信息中心,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646209069440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=2., ext=[AuthorCompanyExt(id=1329869646217458049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1329869646230040962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业信息中心,上海 200040)])]), Author(id=1329869647702241694, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869647811293600, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647702241694, language=EN, stringName=Junlong WANG, firstName=Junlong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869647878402465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647702241694, language=CN, stringName=王俊龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646137766269, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=1., ext=[AuthorCompanyExt(id=1329869646146154878, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646137766269, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869646154543487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646137766269, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1329869647949705635, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, orderNo=6, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869648134255013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647949705635, language=EN, stringName=Bin ZHOU, firstName=Bin, middleName=null, lastName=ZHOU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869648243306918, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, authorId=1329869647949705635, language=CN, stringName=周斌, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.中国医药工业信息中心,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869646209069440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, xref=2., ext=[AuthorCompanyExt(id=1329869646217458049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China), AuthorCompanyExt(id=1329869646230040962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869645458289018, companyId=1329869646209069440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业信息中心,上海 200040)])])]
倪娜1, 潘雪君2, 赵霞2, 兰志龙2, 黄宇2, 王俊龙1, *, 周斌2, *
作者信息
  • 1.中国医药工业研究总院药物临床研究中心,上海 200437
  • 2.中国医药工业信息中心,上海 200040
通讯作者:
周斌,研究员,研究方向:社会管理药学研究;
王俊龙,副研究员,研究方向:创新药物的临床研究。
作者简介:

倪娜,副研究员,研究方向:创新药物的临床研究。

Clinical research progress in immunotherapy of tumor infiltrating lymphocytes
Na NI1, Xuejun PAN2, Xia ZHAO2, Zhilong LAN2, Yu HUANG2, Junlong WANG1, *, Bin ZHOU2, *
Affiliations
  • 1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
  • 2.China National Pharmaceutical Industry Information Center, China State Institute of Pharmaceutical Industry, Shanghai 200040, China
出版时间: 2023-02-10 doi: 10.13683/j.wph.2023.02.001
文章导航
收藏切换

肿瘤浸润淋巴细胞(tumor-infiltrating lymphocyte,TIL)具有高度异质性,TIL的过继性细胞免疫治疗作为免疫治疗的重要手段之一,通过对TIL体外扩增后回输,在多种晚期实体肿瘤中具有治疗作用,且不良反应较少。TIL同时还具有评价抗肿瘤治疗预后的作用。现通过对TIL疗法在不同癌种的临床研究进展、TIL作为肿瘤预后的预测指标的研究进展以及TIL疗法面临的问题进行综述,旨在为后续研究以及TIL疗法在临床上的使用提供依据。

抗肿瘤免疫治疗  /  肿瘤浸润淋巴细胞  /  过继性细胞免疫治疗

Tumor-infiltrating lymphocytes (TIL) has a high degree of heterogeneity. Adoptive cellular immunotherapy is one of the important treatments of immunotherapy. It is effective in many advanced solid tumors treatment with few adverse reactions through TIL reinfusing after expansion in vitro. TIL also has the the role of the effectiveness of anti-tumor therapy. This article reviewed the clinical research progress of TIL therapy in different types of cancer, the research progress of TIL as a predictor of tumor prognosis, and the problems faced by TIL therapy, in order to provide the evidence for follow-up research and the clinical use of TIL therapy.

anti-cancer immunotherapy  /  tumor-infiltrating lymphocytes  /  adoptive cellular immune therapy
倪娜, 潘雪君, 赵霞, 兰志龙, 黄宇, 王俊龙, 周斌. 肿瘤浸润淋巴细胞免疫治疗的临床研究进展. 世界临床药物, 2023 , 44 (2) : 105 -112 . DOI: 10.13683/j.wph.2023.02.001
Na NI, Xuejun PAN, Xia ZHAO, Zhilong LAN, Yu HUANG, Junlong WANG, Bin ZHOU. Clinical research progress in immunotherapy of tumor infiltrating lymphocytes[J]. World Clinical Drug, 2023 , 44 (2) : 105 -112 . DOI: 10.13683/j.wph.2023.02.001

参考文献 引证文献
排序方式:
[1]
杨培培, 昌丽莎, 朱静, 等. 肿瘤浸润淋巴细胞与IncRNA在肿瘤发展中作用的研究进展[J]. 现代肿瘤医学, 2022, 30(6): 1097-1102.
[2]
Rosenberg S, Spiess P, Lafreniere R, et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes[J]. Science, 1986, 233(4770): 1318-1321.
[3]
Amrendra K, Reese W, Anna EV. Cell therapy with TILs: training and taming T cells to fight cancer[J]. Front Immunol, 2021, 12: 690499.
[4]
Amir AJ, Zsiros E, Amaria RN, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma[J]. J Clin Oncol, 2019, 37(15_suppl): 2538.
[5]
Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma[J]. J Clin Oncol, 2021, 39(24): 2656-2666.
[6]
Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study[J]. J Immunother Cancer, 2022, 10(12): e005755.
[7]
Iovance Biotherapeutics, Inc. Iovance biotherapeutics provides update on biologics license application submission for lifileucel in advanced melanoma[EB/OL]. [2022-12-15]. https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-provides-update-biologics-license.
[8]
Pillai M, Jiang Y, Lorigan PC, et al. Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma[J]. Am J Cancer Res, 2022, 12(8): 3967-3984.
[9]
Dafni U, Michielin O, Martin LS, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis[J]. Ann Oncol, 2019, 30(12): 1902-1913.
[10]
Mehta GU, Malekzadeh P, Shelton T, et al. Outcomes of adoptive cell transfer with tumor-infiltrating lymphocytes for metastatic melanoma patients with and without brain metastases[J]. J Immunother, 2018, 41(5): 241-247.
[11]
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040.
[12]
赵毅, 邓鑫. 乳腺癌分子分型与治疗策略[J]. 中国实用外科杂志, 2015, 35(7): 704-708.
[13]
Lee HJ, Kim YA, Sim CK, et al. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer[J]. Oncotarget, 2017, 8(69): 113345-113359.
[14]
Zacharakis N, Huq LM, Seitter SJ, et al. Breast cancers are immunogenic: immunologic analyses and a phase Ⅱ pilot clinical trial using mutation-reactive autologous lymphocytes[J]. J Clin Oncol, 2022, 40(16): 1741-1754.
[15]
Mayor P, Starbuck K, Zsiros E, et al. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies[J]. Gynecol Oncol, 2018, 150(2): 361-369.
[16]
Stevanovi S, Helman SR, Wunderlich JR, et al. A phase Ⅱstudy of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers[J]. Clin Cancer Res, 2019, 25(5): 1486-1493.
[17]
Sakellariou-Thompson D, Forget MA, Hinchcliff E, et al. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy[J]. Cancer Immunol Immunother, 2019, 68(11): 1747-1757.
[18]
Jimeno A, Papa S, Haigentz M, et al. Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC[J]. J Immunoth Cancer, 2020, 8(Suppl 3): A378.
[19]
李疆, 张晓实, 莫浩元, 等. 鼻咽癌患者Epstein-Barr (EB)病毒特异性细胞毒性T淋巴细胞转移继发免疫治疗的临床前期研究[C].//第九届全国肿瘤生物治疗学术会议论文集, 2006: 178-180.
[20]
Creelan BC, Wang C, Teer JK, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial[J]. Nat Med, 2021, 27(8): 1410-1418.
[21]
Massarelli E, Schoenfeld A, Chesney J, et al. A phase 2 multicenter study of iovance autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic NSCLC[J]. J Thorac Oncol, 2021, 16(10): S1012.
[22]
Poch M, Hall M, Joerger A, et al. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer[J]. Oncoimmunology, 2018, 7(9): e1476816.
[23]
李江, 陈耀兵, 陈丽君, 等. 自体肿瘤浸润淋巴细胞联合抗程序性死亡受体-1单抗治疗晚期肝癌的临床研究[J]. 临床外科杂志, 2021, 29(8): 743-747.
[24]
Veliça P, Zech M, Stauss H, et al. Tuning of mTOR in therapeutic T cells as a strategy to manufacture effector and memory T cells[J]. Blood, 2013, 122(21): 4488.
[25]
Khan AB, Carpenter B, Pedro SES, et al. Targeting therapeutic T cells to the bone-marrow niche[J]. Lancet, 2017, 389(1): S55.
[26]
Alsaieedi A, Holler A, Velica P, et al. Safety and efficacy of Tet-regulated IL-12 expression in cancer specific T cells[J]. Oncolmmunology, 2019, 8(3): 1542917
[27]
Eggermont A, Robert C, Soria JC, et al. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors[J]. Oncoimmunology, 2014, 3(1): e27560.
[28]
Toss MS, Miligy I, Al-Kawaza A, et al. Prognostic significance of tumor – infiltrating lymphocytes in ductal carcinoma in situ of the breast[J]. Mod Pathol, 2018, 31(8): 1226-1236.
[29]
Oberg HH, Janitschke L, Sulaj V, et al. Bispecific antibodies enhance tumor – infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors[J]. J Leukoc Biol, 2020, 107(6): 1081-1095.
[30]
杨怀玉, 宣立学. 不同肿瘤浸润淋巴细胞亚型在三阴性乳腺癌中的研究进展[J]. 中华内分泌外科杂志, 2022, 16(2): 237-240.
[31]
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumor-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3 771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018, 19(1): 40-50.
[32]
Würfel F, Erber R, Huebner H, et al. TIL gen: a program to investigate immune targets in breast cancer patients – first results on the influence of tumor-infiltrating lymphocytes[J]. Breast Care (Basel), 2018, 13(1): 8-14.
[33]
Hwang WT, Adams SF, Tahirovic E, et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis[J]. Gynecol Oncol, 2012, 124(2): 192-198.
[34]
De Jong RA, Leffers N, Boezen HM, et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type Ⅰ and Ⅱ endometrial cancer[J]. Gynecol Oncol, 2009, 114: 105-110.
[35]
Hu B, Sun M, Wang Z, et al. Prognostic value of programmed cell death-ligand 1 expression in tumor-infiltrating lymphocytes and viral load in peripheral blood mononuclear cells for Epstein-Barr virus positive nasopharyngeal carcinoma[J]. Clin Chem, 2020, 66(9): 1219-1227.
[36]
Hulen T, Chamberlain CA, Svane IM, et al. ACT up TIL now: the evolution of tumor-infiltrating lymphocytes in adoptive cell therapy for the treatment of solid tumors[J]. Immuno, 2021, 1: 194-211.
[37]
Vignali D, Kallikourdis M. Improving homing in T cell therapy[J]. Cytokine Growth Factor Rev, 2017, 36: 107-116.
[38]
Qu R, Kluger Y, Yang J, et al. Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure[J]. Mol Cancer, 2022, 21(1): 219.
[39]
祝文君, 胡湛斐, 袁周. 肿瘤浸润淋巴细胞在胰腺癌中研究进展[J]. 世界华人消化杂志, 2021, 29(21): 1207-1214.
[40]
邵瑶健, 孟立娜. 肿瘤浸润淋巴细胞在胃癌免疫治疗中的意义[J]. 浙江医学, 2019, 41(22): 2444-2447.
[41]
何天基, 葛波. 肿瘤浸润淋巴细胞在泌尿系肿瘤中的研究进展[J]. 中国免疫学杂志, 2020, 36(14): 1779-1783.
[42]
杨涵, 陈超, 王冲. 肿瘤浸润性淋巴细胞免疫治疗的研究进展[J]. 上海医药, 2022, 43(11): 17-21.
[43]
Zheng L, Qin S, Si W, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells[J]. Science, 2021, 374(6574): abe6474.
2023年第44卷第2期
12
3
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.02.001
  • 接收时间:2023-01-16
  • 首发时间:2026-11-18
  • 出版时间:2023-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2023-01-16
基金
作者信息
    1.中国医药工业研究总院药物临床研究中心,上海 200437
    2.中国医药工业信息中心,上海 200040

通讯作者:

周斌,研究员,研究方向:社会管理药学研究;
王俊龙,副研究员,研究方向:创新药物的临床研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.02.001
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏